StemCell Therapy

A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.

Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia led the research. She and her colleagues tested the effect of venom on clinical subtypes of breast cancer, using the venom from 312 honeybees and bumblebees from Perth Western Australia, Ireland and England.

No one had previously compared the effects of honeybee venom or melittin across all of the different subtypes of breast cancer and normal cells, Dr. Duffy said. We tested honeybee venom on normal breast cells, and cells from the clinical subtypes of breast cancer: hormone receptor positive, HER2-enriched, and triple-negative breast cancer.

Dr. Duffy explained that the goal of the research was ultimately to determine if honeybee venom and its component compound, melittin, had anti-cancer properties.

We found both honeybee venom and melittin significantly, selectively and rapidly reduced the viability of triple-negative breast cancer and HER2-enriched breast cancer cells, said Dr. Duffy. The venom was extremely potent.

Melittin, in particular, also had a surprising effect. Within 20 minutes, the compound was able to reduce the chemical messages of cancer cells that are necessary for growth and cell division.

We looked at how honeybee venom and melittin affect the cancer signaling pathways, the chemical messages that are fundamental for cancer cell growth and reproduction, and we found that very quickly these signaling pathways were shut down, said Dr. Duffy. Melittin modulated the signaling in breast cancer cells by suppressing the activation of the receptor that is commonly overexpressed in triple-negative breast cancer, the epidermal growth factor receptor, and it suppressed the activation of HER2 which is over-expressed in HER2-enriched breast cancer.

Western Australias Chief Scientist Professor Peter Klinken noted that this study significantly demonstrates the potential benefits of melittin, and overall, how compounds in nature can be utilized to combat human diseases.

The researchers note that studies will be necessary to formally assess the best way to deliver melittin to patients.

This is not the only positive news that has come out of the breast cancer treatment realm as of late. Athenex also announced on Sept. 1 that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application for oral paclitaxel and encequidar for the treatment of metastatic breast cancer, and it has been granted Priority Review.

We see oral paclitaxel as a potentially important alternative to IV infusions, especially during the current pandemic, as it may allow cancer patients to take the oral chemotherapy at home, said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex. We believe the oral paclitaxel program validates our broader Orascovery platform, and we are committed to applying the technology to convert other IV chemotherapies into oral agents.

The NDA is based on data from a Phase 3 study of oral paclitaxel for the treatment of metastatic breast cancer. The trial was randomized and controlled, and looked at the safety and efficacy of oral paclitaxel monotherapy against IV paclitaxel monotherapy. It achieved its primary endpoint, demonstrating a statistically significant improvement in overall response rate, along with a lower neuropathy, compared to IV paclitaxel.

The FDA grants Priority Review to NDAs for potential drugs that, if approved, would make significant improvements to the way patients are treated for serious conditions, such as various types of cancer.

See the article here:
Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer? - PharmaLive

Erin Bryant, a physical therapist with Fyzical Therapy, said the body and the brain have the ability to heal with time. In Thieles case, she said, muscle memory and her former level of fitness will aid her recovery.

The therapy practice currently is working with three patients who have had COVID-19, including Thiele. All three cases are different, and all will require different treatment.

Theres no cookie-cutter for this, she said.

Christine Thiele, of Omaha, does a physical therapy session focusing on balance at WW Gym Wellness Workout in Omaha on Wednesday, August 26, 2020. Thiele had COVID-19 in the spring and is still struggling with lingering effects having to do with memory, balance and neuropathy.

Meanwhile, support groups for patients who have had COVID-19 have formed on Facebook and other forums. A group called Body Politic, which includes COVID-19 survivors, also has been involved in research.

Thiele has written about her situation on Facebook. She said doctors believe the virus triggered an autoimmune disease that has affected her mobility.

In the beginning, I was really trying to educate people to take this seriously, she said. Now its like, Look what its done to me. You guys really have to take it seriously.

Steve Schrader, too, has had a long road back.

Now 65, the La Vista man started in mid-March to experience symptoms, which he attributed to allergies. Those symptoms morphed into chest congestion and what he thought was a sinus infection. Schrader, who has asthma, battled it for a couple of weeks, as he usually does with chest congestion, including using a nebulizer.

See original here:
Even after the infection is gone, symptoms linger for COVID-19 'long-haulers' - Omaha World-Herald

MOUNT LAUREL, New Jersey, Sept. 3, 2020 /PRNewswire/ --On October 4-9, 2020, the American Neurological Association, for the first time in its 145-year history, is moving from a traditional meeting format to an interactive, virtual meeting experience. As always, the meeting will explore the latest advances in translational neuroscience, neurobiology of disease and academic neurology. In addition, ANA has announced that it is giving back to the neurological community by providing members with complimentary registration for ANA2020 and significantly reduced registration rates for non-members.

"We recognize that these are unprecedented times, and we are committed to providing meeting access to neurologists and neuroscientists around the world," explained ANA's Executive Director Nadine Goldberg, PhD, MS. "For over 100 years, we have brought together the best researchers and educators in this field, and this year will be no different in that respect, as we transition to an interactive, virtual event." She noted that it is important that all attendees register for the meeting in advance.

Many sessions held during the meeting will be pre-recorded, with live, interactive Q&A sessions following.This year's symposia dives into the science behind recent breakthroughs in our understanding and treatment of neurological disorders across a broad etiological spectrum and will feature talks and poster presentations with latest advances in translational neuroscience, neurobiology of disease, and academic neurology. The four plenary sessions are:

Also, on the schedule are 18 Special Interest Group (SIG) sessions, including Global Neurology, Traumatic Brain Injury, and Neurogenetics. New this year is the Emerging Scholar Lecture series, which is focused on providing junior investigators a platform to discuss their work. In addition, the Derek Denny-Brown Young Neurological Scholar Symposium will feature presentations from the 2020 Derek Denny-Brown awardees, the Wolfe Neuropathy Research Prize and the Grass Foundation-ANA Award in Neuroscience recipients.

ANA Social Justice Symposium to Address Inclusion and Diversity

The ANA is challenging itself to become a champion of 21st century academic neurology and neuroscience. Given that its past was marred by systemic racism, the ANA is working hard to find new ways to rectify these exclusionary practices. To meet these challenges, ANA is redoubling its efforts around inclusion and diversity through educating the neurological community and implementing organizational changes. In line with these efforts, the ANA is hosting its inaugural Social Justice Symposium prior to ANA2020. During this symposium attendees will learn about topics ranging from the impact of social determinants of health on adverse health outcomes for people of color, health policy, and will participate in interactive breakout sessions designed to develop actionable steps to address inequity within academic neurology and neuroscience.

A detailed Advance Program is online at https://2020.myana.org

Follow the meeting live using #ANA2020 on Twitter @TheNewANA1, on Facebook @AmericanNeurologicalAssociation, or on Instagram @ananeurology.

ABOUT THE ANA

The American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them.

For more information, visit http://www.myana.org or follow @TheNewANA1 on Twitter, @AmericanNeurologicalAssociation on Facebook, or @ananeurology on Instagram.

https://2020.myana.org

SOURCE American Neurological Association

Continue reading here:
American Neurological Association Hosts First-Ever All-Virtual Annual Meeting - PR Newswire India

The Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry study now available at Grand View Report, is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix. The report also indicates a pointwise outline of market share, market size, industry partakers, and regional landscape along with statistics, diagrams, & charts elucidating various noteworthy parameters of the industry landscape.

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report offers an exhaustive analysis of this business space. The key trends that define the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market during the analysis timeframe are mentioned in the report, alongside other factors such as regional scope and regulatory outlook. Also, the document elaborates on the impact of current industry trends on key market driving factors as well as top challenges.

Request a sample Report of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market at:https://grandviewreport.com/sample/8560

Covid-19 pandemic affects most industries in the globe. Here at Grand View Report we offer you comprehensive data of related industry which will help and support your business in all possible ways.

Top Key Players Profiled in This Report: , Achelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc

The study also provides with a summary of the competitive spectrum as well as an in-depth assessment of the raw materials and downstream buyers.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

Our study helps to acquire the following:

Elaborating on the competitive landscape of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

A gist of the regional scope of the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

Ask for Discount on Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market Report at:https://grandviewreport.com/discount/8560

Other information mentioned in the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market report:

The report answers important questions that companies may have when operating in the global Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market. Some of the questions are given below:

For More Details On this Report:http://grandviewreport.com/industry-growth/Chemotherapy-Induced-Peripheral-Neuropathy-Treatment-Market-8560

See the rest here:
Global Impact of Covid-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market to Record Significant Revenue Growth During the Forecast...

Global Diabetic Neuropathy Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the Global Diabetic Neuropathy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Diabetic Neuropathy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Diabetic Neuropathy market between 2020 and 2027. In terms of value, the Diabetic Neuropathy industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Get Free Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

The key players profiled in this report include: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion ofDiabetic Neuropathy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographic

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Diabetic Neuropathy market

Table of Contents

Report Overview: It includes the Diabetic Neuropathy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Diabetic Neuropathy market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Diabetic Neuropathy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in theDiabetic Neuropathy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

The research study can answer the following Key questions:

What will be the progress rate of the Diabetic Neuropathy Market for the conjecture period, 2020-2027?What are the prominent factors driving the Diabetic Neuropathy Market across different regions?Who are the major vendors dominating the Diabetic Neuropathy industry and what are their winning strategies?What will be the market scope for the estimated period?What are the major trends shaping the expansion of the industry in the coming years?What are the challenges faced by the Diabetic Neuropathy Market?

Major Highlights of TOC:

Chapter One: GlobalDiabetic Neuropathy Market Industry Overview

1.1Diabetic Neuropathy Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2Diabetic Neuropathy Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: GlobalDiabetic Neuropathy Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Diabetic Neuropathy Market Size by Demand

2.3 Global Diabetic Neuropathy Market Forecast by Demand

Chapter Three: GlobalDiabetic Neuropathy Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2Diabetic Neuropathy Market Size by Type

3.3Diabetic Neuropathy Market Forecast by Type

Chapter Four: Major Region ofDiabetic Neuropathy Market

4.1 Global Diabetic Neuropathy Sales

4.2 Global Diabetic Neuropathy Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Continued here:
Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 - The News Brok

The Cardiac Autonomic Neuropathy Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Cardiac Autonomic Neuropathy Treatment market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Cardiac Autonomic Neuropathy Treatment market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

The worldwide Cardiac Autonomic Neuropathy Treatment market is an enlarging field for top market players,

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

This Cardiac Autonomic Neuropathy Treatment report begins with a basic overview of the market. The analysis highlights the opportunity and Cardiac Autonomic Neuropathy Treatment industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Cardiac Autonomic Neuropathy Treatment insight regarding the things which are driving and affecting the earnings of the market. The Cardiac Autonomic Neuropathy Treatment report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

Research objectives and Reason to procure this report:-

Finally, the global Cardiac Autonomic Neuropathy Treatment market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Cardiac Autonomic Neuropathy Treatment industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Excerpt from:
Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 - Owned

The Diabetic Neuropathy Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Diabetic Neuropathy market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Diabetic Neuropathy market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/4795

The worldwide Diabetic Neuropathy market is an enlarging field for top market players,

the top players

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/4795

This Diabetic Neuropathy report begins with a basic overview of the market. The analysis highlights the opportunity and Diabetic Neuropathy industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Diabetic Neuropathy insight regarding the things which are driving and affecting the earnings of the market. The Diabetic Neuropathy report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/4795

Research objectives and Reason to procure this report:-

Finally, the global Diabetic Neuropathy market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Diabetic Neuropathy industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Read the original here:
Value of Diabetic Neuropathy Market Predicted to Surpass US$ by the of 2015 2021 - Scientect

I have often tried gabapentin (Neurontin) or a similar drug, pregabalin (Lyrica), but have not had much success. Duloxetine (Cymbalta) has evidence showing effectiveness at reducing pain and improving numbness, and those treated with duloxetine had a better quality of life than those on placebo. Finally, a preliminary trial showed a compounded cream containing baclofen, amitriptyline and ketamine showed some benefit.

Dear Dr. Roach An ear, nose and throat specialist told me not to use nasal sprays that contain oxymetazoline, such as Afrin, since over time they will damage and erode the tissues of the septum and inner nose. He said to use simple salt solution instead. Is this true? I used two shots of this nasal spray, and it cleared my sinuses and nose but was very uncomfortable. I have to be careful since I have had a constructive rhinoplasty and a septoplasty with reduced tissues. S.L.

Answer I agree wholeheartedly with your ENT doctor that long-term use of oxymetazoline nasal sprays, such as Afrin, can cause problems with the lining of your nasal passages. However, there are some times when Afrin or similar sprays are helpful. I have recommended it for people with colds or sinus infections before going on a plane, for example, since it is very effective in short-term use (no more than three days).

Read more here:
Is there any help for chemotherapy-induced neuropathy? - STLtoday.com

Patients with newly diagnosed ovarian cancer who received weekly chemotherapy reported a lower mean quality of life (QOL) compared to patients who received the standard treatment every three weeks, according to results of a recent study published in The Lancet Oncology.

The primary endpoint of the iCON8 study also found that patients who received weekly chemotherapy saw no increase in progression-free survival (PFS) compared to patients who received the standard treatment, making it a poor choice for the management of newly diagnosed ovarian cancer.

Prior to this study, the phase 3 JGOG-3016 trial in Japan found that weekly paclitaxel combined with three-weekly carboplatin improved PFS and overall survival (OS) when compared to standard treatment in Japanese patients with advanced disease. But given the increasing evidence of the difference in response to treatment between Asian and white populations, the creators of the ICON8 trial set out to build on these results and determine if the same survival advantage could be found in a mostly European population.

While PFS was the primary endpoint of the ICON8 trial, the secondary endpoints examining QOL in these patients are what the Lancet analysis focused on.

The open-label, randomized, controlled phase 3 study included patients from 117 hospital sites in the UK, Australia, New Zealand, Mexico, South Korea and the Republic of Ireland, between June 6, 2011 and November 28, 2014. All patients were then randomly assigned to one of three groups:

All patients had either epithelial ovarian, primary peritoneal or fallopian tube carcinoma (collectively termed ovarian cancer in the study) and had not received previous systemic therapy for their ovarian cancer.

Out of the 1,566 patients in the study, 1,540 completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-OV28 questionnaires. The QLQ-C30 includes questions that measure a global health status score, function scales to determine physical, role, emotional, cognitive, and social QOL, and symptom scales to measure fatigue, nausea or vomiting, pain, insomnia, appetite loss, constipation, diarrhea, and financial difficulties. The QLQ-OV28 measures experiences more specific to ovarian cancer, including abdominal or gastrointestinal symptoms, peripheral neuropathy, chemotherapy side effects, hormonal or menopausal symptoms, and other factors.

These questionnaires were completed by patients during outpatient attendances at day one of each chemotherapy cycle, and during follow-up visits every six weeks until nine months from randomization, then every three months for the next 2 years, and finally, every six months for up to five years from randomization. Researchers also had patients complete these surveys at six-month intervals after disease progression.

Baseline questionnaires were completed by 1,438 (92%) of patients, and of the 1,280 patients available for 9-month follow-up questionnaires 882 patients (69%) contributed data to that set. When accounting for patients who dropped out of the study due to disease progression, withdrawal or death, a total of 828 patients contributed QOL data both at 9 months and baseline.

Upon examination, the researchers found no significant difference in the global health score at 9 months between the study groups, but upon a longitudinal analysis, found lower global health scores for those receiving weekly paclitaxel compared to patients who received the standard chemotherapy every three weeks.

We found no evidence of a difference in global quality of life between treatment groups at 9 months; however, patients receiving weekly treatment reported lower mean quality of life across the 9-month period after randomization, the authors concluded.

Taken together with the lack of progression-free survival benefit, these findings do not support routine use of weekly paclitaxel-containing regimens in the management of newly diagnosed ovarian cancer.

Excerpt from:
Increased Chemotherapy Leads to Lower Quality of Life in Newly Diagnosed Ovarian Cancer - Curetoday.com

I find the level of attention to individual patient's needs excellent, including diligent work to remove many roadblocks to primary and advanced care, he said. This is one of the most important functions of a free clinic, requiring coordination with pharmacies, state benefit programs, hospital systems, transportation, and family caregivers. It's a blessing to be associated with them.

The Mullins clinic is open on Monday and Wednesday while the Marion clinic is open Tuesdays and Thursdays. Hours of operation are from 8 a.m. to 5 p.m.

To qualify, visitors must be a Marion County resident, 18 years of age or older, not receiving any health insurance and income 200 percent below federal poverty guidelines.

For more information call 843-464-8750 or 843-423-5212.

Helping Hands Free Medical Clinic Services:

Health Education, TB Skin Tests, Labs, EKG and Radiology, Urinalysis, A1Cs, Medications, Flu & HEP A Vaccines, STD Screenings, PAP Smear Exams & Mammograms, Family Planning, a Diabetes & Hypertension Program, Cancer Screenings, Retinopathy & Neuropathy Exams, Screenings for Hearing, Dental Service Assistance, Wound Care Clinic, Cardiology Clinic, COVID-19 tests and referrals.

Here is the original post:
Helping Hands Free Medical Clinic continues to make impact in Marion County more than 20 years later - SCNow

Company successfully completes warrant repricing and exchange, with gross proceeds to total $10.5 million

Company Enters Negotiation for Potential Licensing of Neuropathies Asset

PRINCETON, NJ / ACCESSWIRE / August 14, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th, 2020 and provided a business update.

Pankaj Mohan, Ph.D., Founder and CEO commented, "During the quarter, we made exceptional progress advancing our pipeline of oncology candidates, as well as announced an exciting new program to explore opportunities in the antiviral arena. These accomplishments were complemented by our strategic licensing activities, that included a potential partnership for the development of our low-dose IL-6 asset (SON-081) in diabetic peripheral neuropathy, an indication with significant commercial potential."

First Quarter and Recent Corporate Updates

Sonnet is pleased to provide the following updates on its pipeline assets:

Initial preclinical proof-of-concept work has been completed with both GMcSF and IL-18 and with GMcSF and IL-12 in a xenograft mouse model of melanoma. This study was designed to evaluate preclinical activity of the concomitantly administered cytokines as FHAB-derived molecules, using Sonnet's Fully Human Albumin Binding (FHAB) technology, in several groups of tumor-bearing mice. Sonnet's FHAB-derived drug candidates all showed significant reduction in tumor growth compared to placebo and when compared to cytokines not derived from the Company's platform.

Additionally during the quarter, the Company executed a letter of intent to negotiate an agreement to license its SON-081 and SON-080 assets, both low-dose formulations of Interleukin 6 (IL-6), for diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) to New Life Therapeutics Pte. Ltd. of Singapore. The licensed territory would include the ASEAN countries of Singapore, Malaysia, Indonesia, Thailand, The Philippines, Cambodia, Brunei, Vietnam, Myanmar and Lao PDR. The transaction is subject to execution of a definitive agreement to be negotiated between Sonnet and New Life. Sonnet is scheduled to receive $500,000 upon final execution of the letter of intent from New Life and could receive an additional $3.5 million in license fees upon execution of the definitive agreement. The letter of intent also stipulates up to $36 million in milestone payments and a royalty of 30% on commercial sales, payable to Sonnet.

As previously announced, COVID-19 has impacted the speed at which the Company is completing some trials, but the Company remains on track to submit an IND for SON-080 in the first half of 2021 and SON-1010 in the second half of 2021. The Company also expects to accrue additional pre-clinical data for its various pipeline products over the coming months, some of which may be appropriate for presentation at upcoming medical conferences.

Fiscal 2020 Third Quarter Ended June 30, 2020 Financial Results

As previously reported, on April 1, 2020, the Company completed its merger transaction with Sonnet Sub, whereby Sonnet Sub became a wholly owned subsidiary of the Company, and the business of Sonnet Sub became that of the Company. On April 2, 2020, the Company's common stock began trading on The Nasdaq Capital Market under the symbol "SONN."

Jay Cross, CFO, elaborated on the Company's capital structure, saying, "With the warrant exchange transaction completed, we have good visibility into our pro forma fully diluted share count. At approximately 29.3 million shares, assuming the exercise of the remaining Series A warrants, the share count is significantly below the potential 39.7 million shares that could have existed under the original terms of the $19.0 million private placement transaction. Importantly, this new pro forma number includes 11.3 million Series C warrants that, if exercised, would bring in gross proceeds to the Company of $36.1 million."

About Sonnet BioTherapeutics Holdings, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Story continues

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Sonnet Biotherapeutics Investor Contact

Alan LadaSolebury Trout617-221-8006alada@soleburytrout.com

Sonnet BioTherapeutics Holdings, Inc.Balance Sheets(unaudited)

Assets

Current assets:

Cash

Prepaid expenses other current assets

Total current assets

Property and equipment

Operating lease right-of-use asset

Other assets

Total assets

Liabilities and stockholders' equity (deficit)

Current liabilities:

Related-party notes

Accounts payable

Accrued expenses

Operating lease liability

Total current liabilities

Note payable

Operating lease liability

Total liabilities

Commitments and contingencies (note 8)

Stockholders' equity (deficit):

Preferred stock; $0.0001 par value: 5,000,000 shares authorized. No shares issued or outstanding

Common stock; $0.0001 par value: 125,000,000 shares authorized; 9,200,176 and 5,547,643 issued and outstanding at June 30, 2020 and September 30, 2019, respectively

Additional paid-in capital

Accumulated deficit

Total stockholders' equity (deficit)

Total liabilities and stockholders' equity (deficit)

Sonnet BioTherapeutics Holdings, Inc.Statements of Operations(unaudited)

Operating expenses:

Research and development

Acquired in-process in-process research and development

General and administrative

Loss from operations

Interest income (expense)

Foreign exchange loss

Net loss

Per share information:

Net loss per share of common stock, basic and diluted

Weighted average shares outstanding, basic and diluted

SOURCE: Sonnet BioTherapeutics Holdings, Inc.

View source version on accesswire.com: https://www.accesswire.com/601648/Sonnet-BioTherapeutics-Provides-Fiscal-Year-Third-Quarter-Business-and-Earnings-Update

Link:
Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update - Yahoo Finance

New Jersey, United States,- Latest update on Diabetic Neuropathy Drugs Market Analysis report published with extensive market research, Diabetic Neuropathy Drugs Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Diabetic Neuropathy Drugs industry. With the classified Diabetic Neuropathy Drugs market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Diabetic Neuropathy Drugs market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Diabetic Neuropathy Drugs market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Diabetic Neuropathy Drugs Market growth opportunities in the industry.

Diabetic Neuropathy Drugs Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Diabetic Neuropathy Drugs market size, volume and value, as well as price data.

Diabetic Neuropathy Drugs Market competition by top Manufacturers:

Diabetic Neuropathy Drugs Market Classification by Types:

Diabetic Neuropathy Drugs Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Diabetic Neuropathy Drugs Market Report:

Cataloging the competitive terrain of the Diabetic Neuropathy Drugs market:

Unveiling the geographical penetration of the Diabetic Neuropathy Drugs market:

The report of the Diabetic Neuropathy Drugs market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Diabetic Neuropathy Drugs Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Diabetic Neuropathy Drugs Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

More here:
Diabetic Neuropathy Drugs Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 -...

We are afforded opportunities daily to be gracious and merciful. It is a superpower to be embraced: the ability to treat someone who offended you with compassion; choosing to be kind and forgiving.

Matthew 5:9, the Messiah declares, Blessed are the peacemakers, for they shall be called the sons of God.

Yet, how does this impact the exchange when the store clerk gives you a hard time with a return; when that car in front of you turns abruptly without signaling; or when a friend betrays your confidence and shares your personal matters with others.

We are afforded opportunities daily to be gracious and merciful. It is a superpower to be embraced: the ability to treat someone who offended you with compassion; choosing to be kind and forgiving. We must resist the knee-jerk reaction to respond in anger as the quick go-to emotion. We are called to seek peace over confusion.

Notice Jesus did not say blessed are the peacekeepers! A peacekeeper seeks to sustain peace by evading conflict and would usually attempt to steer clear of different positions to keep others content. A peacemaker is someone committed to resolving inner and outer chaos in order to establish peace with others and within themselves.

One can be a peacemaker even in protesting seeking to make every effort to keep the unity of the Spirit through the bond of peace. (Ephesians 4:3)

Jesus was a peacemaker but notice: He never avoided conflict. By His example, we can speak truth to power with appropriate passion and constraint. In fact, peacemaking is grace and mercy in action. A peacekeeper may have false illusions that everything is fine because of the absence of tension and conflict. However, that does not mean all is well. Neuropathy is a medical condition that can be masked by numbness; likewise one can be spiritually numb to the challenges among them.

A friend, Candys Mayo, shared Learn the difference between a leader and an instigator. Leaders deposit into the community that they serve, they spread a positive and encouraging message. They might even call you out on something you have done, but they do so privately and in a way that teaches and doesn't degrade. Thats agitation which is different from instigation. An instigator casts judgment, spreads rumors, negativity and withdraws energy from everyone else because they truly lack value, substance and creativity. They have to withdraw from others to cover up their own insecurities. Be a leader. Teach, don't tear down.

Michael Jacksons Man in the Mirror, with socially- conscious infused lyrics, If you want to make the world a better place, take a look at yourself and make a change!

You and I must foster environments of reconciliation where persons beyond race, gender, sexual orientation and faith can have civil, candid and courageous conversations about real differences as well as real agreements with the goal of establishing genuine relationships.

Who would disagree that our civil life is diminishing, especially in the political arena? When did it become standard for political discourse to turn into venomous and vitriol rancor? Who decided that insults are more potent than ideas? Hatred and discrimination should have no place in a civil society. Please realize this message is not meant to target any one individual as much as sharing a hope that we reject every act which demeans and derides others.

Can I make a personal pitch for civility? Let's agree to pledge to be more positive and polite while also having the willingness to confront offensive words with corrective action. Silence about incivility is not golden. Samuel Johnson, a philosopher once said When the forms of civility are violated, there remains little hope of a return to kindness or decency."

Understand, God is not going to hold others responsible for your decisions or responses to their actions. I often reflect upon the message was found written on the wall in Mother Teresa's home for children in Calcutta:

People are often unreasonable, irrational, and self-centered. Forgive them anyway.If you are kind, people may accuse you of selfish, ulterior motives. Be kind anyway.If you are successful, you will win some unfaithful friends and some genuine enemies. Succeed anyway.If you are honest and sincere people may deceive you. Be honest and sincere anyway.What you spend years creating, others could destroy overnight. Create anyway.If you find serenity and happiness, some may be jealous. Be happy anyway.The good you do today, will often be forgotten. Do good anyway.Give the best you have, and it will never be enough. Give your best anyway.In the final analysis, it is between you and God. It was never between you and them anyway.

Matthew 5: 43-44 reflects that People say love your neighbor and hate your enemy but I tell you to love your enemies and pray for anyone who mistreats you. Stop focusing on those you perceive are against you. In fact, loving your neighbor is easy-peasy! Its loving and praying for those who dislike you that is the real exercise. In many ways, treat your friend and your enemies with equal compassion, love and concern. After all, that's how God operates.

Notice its not about your feelings. Nor, should you feel good about having an enemy. However, it is always a decision of your will to respond proactively instead of reactively. Continuing this behavior as part of your lifestyle may ultimately result in that enemy becoming a friend.

Bishop Timothy J. Clarke First Church of God in Columbus references Psalms 23:5 to assert The Lord prepares a table before me in the presence of my enemies. Stop looking at your enemies and start focusing on your table. My table has love, mercy, provision, peace blessing! Why should I focus on my enemies where there is so much on my table?

So you dont have to force a smile or mutter softly as not to be heard to keep the peace. Own them but dont keep them! Those feelings when given the One full of grace is bright enough to melt in the light of His mercy as you endure and keep the faith.

Rev. Lewis W. Macklin II is the lead pastor of Holy Trinity Missionary Baptist Church, chaplain for the Youngstown Police Department and coordinator of the Mahoning Valley African American Male Wellness Walk. He resides in Youngstown with Dorothy, his partner in marriage and ministry. They share the love and joy of 5 children and 6 grandchildren.

All biblical references cited are New International Version unless otherwise noted.

See the original post:
KEEPING THE FAITH | Even when it's hard, love your enemies - Mahoning Matters

The Diabetic Neuropathy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202029 report covers all of the aspects required to gain a complete understanding of the pre-market conditions, current conditions as well as a well-measured forecast. This report also researches and evaluates the impact of the Covid-19 outbreak on the Diabetic Neuropathy Market, involving potential opportunity and challenges, drivers, and risks. We present the impact assessment of Covid-19 effects on Diabetic Neuropathy Market and market growth forecast based on different scenarios (optimistic, pessimistic, very optimistic, most likely, etc.).

The research report provides a comprehensive review of the global market. Analysts have identified the key drivers and restraints in the overall market. They have studied the historical milestones achieved by the global Diabetic Neuropathy Market and emerging trends. A comparison of the two has enabled the analysts to draw a potential trajectory of the global Diabetic Neuropathy Market for the forecast period.

For Better Understanding,Download FREE Exclusive PDF Sample Copy Of This Research Report:https://marketresearch.biz/report/diabetic-neuropathy-market/request-sample

For making the research report exhaustive, the analysts have included Porters five forces analysis and SWOT analysis. Both these assess the path the market is likely to take by factoring strengths, weaknesses, opportunities, and threats. Porters five forces analysis elucidates the intensity of the competitive rivalry and the bargaining power of suppliers and buyers. Furthermore, the research report also presents an in-depth explanation of the emerging trends in the global Diabetic Neuropathy Market and the disruptive technologies that could be key areas for investment.

Important Features that are under offering & key highlights of the report:

Detailed overview of Diabetic Neuropathy Market

Changing market dynamics of the Diabetic Neuropathy industry

In-depth Diabetic Neuropathy market segmentation by disorder type, treatment, and region etc

Historical, current and projected market size in terms of value and volume

Recent industry trends and developments

Competitive landscape of Diabetic Neuropathy Market

Strategies of key players and product/service offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Diabetic Neuropathy Market performance

Download FREE Sample PDF Report Here

Competition Analysis:

As the markets have been advancing the competition has increased by manifold and this has completely changed the way the competition is perceived and dealt with and in our report, we have discussed the complete analysis of the competition and how the big players in the Diabetic Neuropathy Market have been adapting to new techniques and what are the problems that they are facing.

Our research, which provides a comprehensive overview of mergers and acquisitions, will help you gain a full insight into market dynamics and will also give you a thorough knowledge of how to succeed and develop in the market.

The Leading Market Players Covered in this Report are:

Pfizer Inc, Eli Lilly and Company, Actavis Pharma Inc, Cephalon Inc, Meda Pharma GmbH, GlaxoSmithKline plc, NeuroMetrix Inc, Johnson & Johnson Inc, Boehringer Ingelheim GmbH, Astellas Pharma Inc

Global Diabetic Neuropathy Market Market: Segmentation

The chapters of segmentation allow the readers to understand the aspects of the market such as its products/service, available technologies, and applications of the same. The research report also offers valuable information on emerging developments that are likely to decide the success of these segments in the coming years.

Regions Covered in the Global Diabetic Neuropathy Market:

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Germany, Turkey, Russia UK, France, Italy, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The Middle East and Africa (GCC Countries and Egypt)

Inquire/Speak To Expert for Further Detailed Information About Diabetic Neuropathy Market Research Report:https://marketresearch.biz/report/diabetic-neuropathy-market/#inquiry

Table Of Content:

Chapter 1: Introduction, market driving force, product/service scope, market risk, overview, and opportunities of the global Diabetic Neuropathy Market

Chapter 2: Evaluating the leading players of the global Diabetic Neuropathy Market which consists of its revenue, sales, and price of the products

Chapter 3: Displaying the competitive nature among key players, with market share, revenue, and sales

Chapter 4: Presenting global Diabetic Neuropathy Market by regions, market share and with revenue and sales for the projected period

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by players with revenue share and sales by key countries in these various regions

GetDetailed Table Of Contents:https://marketresearch.biz/report/diabetic-neuropathy-market/#toc

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel:+ 1-347-826-1876

Email ID:inquiry@marketresearch.biz

Website:https://marketresearch.biz/

Read Our Top Trending Research Reports:

Read:Latest Research: Mining Waste Management Market Research Report With COVID-19 Impact 2020-2029

Read:LED Grow Light Market Impact Of COVID-19: Regional Outlook, Trends, Key Companies Profile, CAGR And Forecast 2029

Link:
Global Diabetic Neuropathy Market 2020-2029 : Do You Really Need It? This Research Will Help You Decide! - News Monitoring

Diabetic Neuropathy Drugs Market 2019: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Diabetic Neuropathy Drugs market for period of 2019 to 2025. As per the analysis provided in the report, the global market of Diabetic Neuropathy Drugs is estimated to growth at a CAGR of _% during the forecast period 2019 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Diabetic Neuropathy Drugs market was valued at USD _ million/billion.

This research report based on Diabetic Neuropathy Drugs market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Diabetic Neuropathy Drugs market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Diabetic Neuropathy Drugs industry.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2694284&source=atm

Diabetic Neuropathy Drugs Market Overview:

The Research projects that the Diabetic Neuropathy Drugs market size will grow from in 2019 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2019, and the market size is projected from 2019 to 2024.

segment by Type, the product can be split intoCalcium Channel Alpha-2 Delta LigandSNRIs and TCAsOthersMarket segment by Application, split intoHospitalsDrug StoresOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global Diabetic Neuropathy Drugs status, future forecast, growth opportunity, key market and key players.To present the Diabetic Neuropathy Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Diabetic Neuropathy Drugs are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2694284&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2694284&licType=S&source=atm

The Questions Answered by Diabetic Neuropathy Drugs Market Report:

And Many More.

The report on the global Diabetic Neuropathy Drugs market covers 12 sections as given below:

See the original post here:
Diabetic Neuropathy Drugs Projected to be Resilient During 2019-2025 - Jewish Life News

Georgetown, Kentucky, July 07, 2020 (GLOBE NEWSWIRE) -- Ecofibre Limited (Ecofibre, Company) (ASX:EOF, OTC-NASDAQ Intl Designation: EOFBF) is pleased to announce that the Lankenau Institute for Medical Research1 (LIMR) has begun patient enrollment in a Phase II clinical trial using Ananda Health hemp-derived CBD.

The purpose of this study is to assess the efficacy of a hemp-based cannabidiol (CBD) product, Ananda Health Spectrum gelcaps, on the severity and duration of chemotherapy-induced peripheral neuropathy (CIPN) among breast, colon, and ovarian cancer patients who received common types of neurotoxic chemotherapy.

Ecofibre and Ananda demonstrate their commitment to advancing the science of CBD with the launch of the Coala-T-CBD study2 (ClinicalTrials.gov Identifier: NCT04398446). The phase II clinical trial began enrolling patients at LIMR in June.

The debilitating condition, CIPN, is often chronic, compromising patients quality of life and limiting their ability to complete a full course of potentially life-saving treatments. Currently, there are no safe and effective medications to treat or prevent CIPN, but research in animals using CBD offers hope as a new treatment.

The Coala-T-CBD StudyTMis the first clinical trial positioned to translate this success to humans and is led by oncologist Dr. Marisa Weiss, the founder and chief medical officer of http://www.Breastcancer.org and Director of Breast Radiation Oncology and Breast Health Outreach at Lankenau Medical Center.

We are proud to be the first in the United States to study the impact of hemp-derived full spectrum CBD on CIPN, a condition that affects approximately 25-50% of pediatric and adult cancer patients undergoing neurotoxic chemotherapy, Weiss states. Among other milestones, the Coala-T-CBD StudyTMreceived an IND (investigational new drug) by the Food and Drug Administration (FDA) and will use Ananda softgels in the study protocol.

To our knowledge, this is the first phase II clinical trial using full-spectrum hemp extract for the treatment of CIPN to receive an FDA IND. This level of research is necessary to answer the global call from the medical community, patients, and regulatory bodies seeking effective treatment of this difficult, common chemotherapy side effect, says Weiss. The IND allows for Weiss team to conduct the highest-quality research using a randomized, double-blind, placebo-controlled clinical trial.

Ananda Health Research Portfolio

The FDA has publicly requested data on hemp-derived CBD regarding tolerability, drug interactions, toxicity, and dosing. Ecofibre responded early by investing an additional USD $1.8 million in research across several studies.

In 2019, the company published a peer-reviewed study3regarding the effects of low-dose CBD in chronic pain patients. The results demonstrated that low-dose CBD was well tolerated and improved pain, sleep, mood and opioid use.

The Coala-T-CBD StudyTMcontributes to Ecofibres growing clinical research portfolio of CBD use across age groups, populations, disease states, and doses. Importantly, the Coala-T-CBD StudyTMwill offer critical insights on the use of higher-dose CBD.

Ecofibres second phase II clinical trial4(ClinicalTrials.gov Identifier: NCT04436081) will evaluate moderate-dose CBD on agitation, sleep and mood in dementia patients. The moderate-dose study is currently pursuing its own FDA IND and expects patient enrollment in August.

Both the Coala-T-CBD StudyTMand the dementia study include comprehensive physician and laboratory analyses to determine the safety of moderate and higher-dose CBD.

In addition to its clinical trials in the U.S., Ecofibre will be supporting research on low-dose full spectrum CBD later this year in Australia.

Alex Capano, Ecofibres Chief Science Officer states, These studies will provide solutions for patients and contribute valuable data on the safety and efficacy of hemp CBD products. We understand the critical need for more sophisticated, rigorous research and are dedicated to closing those gaps.

Ecofibre CEO, Eric Wang adds, A core foundation for Ananda Health has been to support quality research for patient and practitioner education. Whilst the recent pandemic has created market uncertainty, the Company remains highly committed to its long-term investment to support our customers and the FDA in creating the knowledge base to inform better decisions for our industry.

We are pleased to work with such a high-quality group of researchers and physicians at LIMR. The Coala-T-CBD StudyTMwill provide ongoing updates and anticipates completion in 2022.

For more information on Ecofibre Limited, visitwww.ecofibre.com.

About EcofibreEcofibre is a provider of hemp products in the United States and Australia.

In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See http://www.anandahemp.com and http://www.anandaprofessional.com.

In Australia, the Company produces 100% Australian grown and processed hemp food products including protein powders, de-hulled hemp seed and hemp oil. See http://www.anandafood.com.

The Company is also developing innovative hemp-based products in textiles and composite materials in partnership with TexInnovate in the United States. See http://www.hempblack.com.

The Company owns or controls key parts of the value chain in each business, from breeding, growing and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products.

About Main Line Health

Main Line Health is a not-for-profit health system serving portions of Philadelphia and its western suburbs. At its core are four of the regions most respected acute care hospitalsLankenau Medical Center, Bryn Mawr Hospital, Paoli Hospital and Riddle Hospitalas well as one of the nations premier facilities for rehabilitative medicine, Bryn Mawr Rehabilitation Hospital.

Main Line Health also includes the Lankenau Institute for Medical Research, a non-profit biomedical research organization on the campus of Lankenau Medical Center, dedicated to advancing an understanding of the causes of cancer, diabetes and heart disease to help improve diagnosis and treatment as well as prevention.

About Breastcancer.org

Breastcancer.org is a patient-centric resource for breast health and breast cancer information and support. Our research drives our ability to engage, educate, and empower people with breast cancer with expert information and dynamic peer support community to help them make the best decisions for their lives. The nonprofit organization was founded by breast oncologist Marisa C. Weiss, M.D. and born out of her conviction that women with breast cancer need more information and support than a physician visit can provide. Breastcancer.org receives more than 30 million visits each year. For more information about Breastcancer.org, please visit http://www.Breastcancer.org.

Read more here:
ECOFIBRE LIMITED Ananda Health products used in first FDA authorized clinical trial on hemp-derived CBD to treat chemotherapy induced peripheral...

DUBLIN--(BUSINESS WIRE)--haThe "Global Diabetic Neuropathy Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights into the Diabetic Neuropathy pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. This research analyzes and forecasts the Diabetic Neuropathy market size and drug sales. It also provides insights into Diabetic Neuropathy epidemiology and late stage pipeline.

This research covers the following: Diabetic Neuropathy treatment options, Diabetic Neuropathy late stage clinical trials pipeline, Diabetic Neuropathy prevalence by countries, Diabetic Neuropathy market size and forecast by countries, key market events and trends, drug sales and forecast by countries, and market shares by countries. The research scope includes the countries US, Germany, France, Italy, Spain, UK, Japan, Europe, Global (G7 Countries).

Research Scope:

Benefits of this Research:

Key Topics Covered:

1. Diabetic Neuropathy Treatment Options

2. Diabetic Neuropathy Pipeline Insights

2.1. Diabetic Neuropathy Phase 3 Clinical Trials

2.2. Diabetic Neuropathy Phase 2 Clinical Trials

2.3. Diabetic Neuropathy Phase 1 Clinical Trials

3. Diabetic Neuropathy Epidemiology Analysis by Countries

4. US Diabetic Neuropathy Market Insights

4.1. Marketed Drugs for Diabetic Neuropathy in US

4.2. US Diabetic Neuropathy Market Size & Forecast

4.3. US Diabetic Neuropathy Drugs Sales & Forecast

4.4. US Diabetic Neuropathy Market Share Analysis

5. Germany Diabetic Neuropathy Market Insights

5.1. Marketed Drugs for Diabetic Neuropathy in Germany

5.2. Germany Diabetic Neuropathy Market Size & Forecast

5.3. Germany Diabetic Neuropathy Drugs Sales Forecast

5.4. Germany Diabetic Neuropathy Market Share Analysis

6. France Diabetic Neuropathy Market Insights

6.1. Marketed Drugs for Diabetic Neuropathy in France

6.2. France Diabetic Neuropathy Market Size & Forecast

6.3. France Diabetic Neuropathy Product Sales Forecast

6.4. France Diabetic Neuropathy Market Share Analysis

7. Italy Diabetic Neuropathy Market Insights

7.1. Marketed Drugs for Diabetic Neuropathy in Italy

7.2. Italy Diabetic Neuropathy Market Size & Forecast

7.3. Italy Diabetic Neuropathy Product Sales Forecast

7.4. Italy Diabetic Neuropathy Market Share Analysis

8. Spain Diabetic Neuropathy Market Insights

8.1. Marketed Drugs for Diabetic Neuropathy in Spain

8.2. Spain Diabetic Neuropathy Market Size & Forecast

8.3. Spain Diabetic Neuropathy Product Sales Forecast

8.4. Spain Diabetic Neuropathy Market Share Analysis

9. UK Diabetic Neuropathy Market Insights

9.1. Marketed Drugs for Diabetic Neuropathy in UK

9.2. UK Diabetic Neuropathy Market Size & Forecast

9.3. UK Diabetic Neuropathy Product Sales Forecast

9.4. UK Diabetic Neuropathy Market Share Analysis

10. Europe Diabetic Neuropathy Market Insights

10.1. Europe Diabetic Neuropathy Market Size & Forecast

10.2. Europe Diabetic Neuropathy Product Sales Forecast

10.3. Europe Diabetic Neuropathy Market Share Analysis

11. Japan Diabetic Neuropathy Market Insights

11.1. Marketed Drugs for Diabetic Neuropathy in Japan

11.2. Japan Diabetic Neuropathy Market Size & Forecast

11.3. Japan Diabetic Neuropathy Product Sales Forecast

11.4. Japan Diabetic Neuropathy Market Share Analysis

12. Global Diabetic Neuropathy Market Insights

12.1. Global Diabetic Neuropathy Market Size & Forecast

12.2. Global Diabetic Neuropathy Product Sales Forecast

12.3. Global Diabetic Neuropathy Market Share Analysis

13. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/vu5c4h

Read this article:
2020 Insights into the Global Diabetic Neuropathy Industry - Market and Competitive Landscape - ResearchAndMarkets.com - Business Wire

Janette Bowers lives with neuropathy and can now feel her feet again, thanks to Advanced Nerve and Health Center

HOUSTON Advanced Nerve and Health Center has a solution for those who suffer from nerve pain, or neuropathy. The treatment developed by Dr. Bao Thai is non-invasive, pain free and helps the body repair the nerves without surgery or medication.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $29, get a tele-health visit with a member of Dr. Thai's team, an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if you are a good candidate for the process. This is a $249 value.

Call 832-626-1260 to book your appointment.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

For more information, log on to NerveAndHealth.com.

This content sponsored by Advanced Nerve and Health Center.

Read this article:
Real relief from neuropathy with Advanced Nerve and Health Center - KHOU.com

Global Neuropathy Pain Treatment Market 2020-2024 The analyst has been monitoring the neuropathy pain treatment market and it is poised to grow by $ 1702. 89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast period.

New York, July 07, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Neuropathy Pain Treatment Market 2020-2024" - https://www.reportlinker.com/p04796571/?utm_source=GNW Our reports on neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the presence of large patient pool and focus toward the development of novel therapeutics for postherpetic neuralgia. The neuropathy pain treatment market analysis includes type segment and geographic landscape.

The neuropathy pain treatment market is segmented as below: By Type Diabetic neuropathy Chemotherapy-induced neuropathy pain Postherpetic neuralgia Others

By Geographic Landscapes North America Europe APAC South America MEA

This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our neuropathy pain treatment market covers the following areas: Neuropathy pain treatment market sizing Neuropathy pain treatment market forecast Neuropathy pain treatment market industry analysis

Read the full report: https://www.reportlinker.com/p04796571/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Go here to read the rest:
The Global Neuropathy Pain Treatment Market is expected to grow by $ 1702.89 mn during 2020-2024 progressing at a CAGR of 5% during the forecast...

The Global Ischemic Optic Neuropathy Treatment market gives detailed Evaluation about all the Important aspects related to the marketplace. The analysis on global Ischemic Optic Neuropathy Treatment economy, offers profound insights regarding the Ischemic Optic Neuropathy Treatment market covering all of the crucial aspects of the market. Moreover, the report offers historical information with future prediction over the forecast period. Various important factors such as market trends, earnings growth patterns market shares and demand and supply are contained in almost all the market research report for every industry. A number of the vital facets analysed in the report contains market share, production, key regions, earnings rate in addition to key players.

The study of various segments of the global market are also Covered in the study report. In addition to that, for the prediction periods determination of variables such as market size and the competitive landscape of this sector is analysed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The study report provides the in-depth analysis of all these tendencies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23077

In addition, the Ischemic Optic Neuropathy Treatment market report also provides the Latest trends in the Global Ischemic Optic Neuropathy Treatment marketplace with the help of primary as well as secondary research methods. Additionally, the research report on Ischemic Optic Neuropathy Treatment market provides a wide analysis of the market including market overview, production, producers, dimensions, price, value, growth rate, earnings, prices, export, consumption, and sales revenue of this Global Ischemic Optic Neuropathy Treatment market. On the flip side, the Ischemic Optic Neuropathy Treatment market report also studies the industry status for the prediction period. However, this can help to grow the advertising opportunities throughout the world in addition to major market suppliers.

key players and product offerings

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23077

The Ischemic Optic Neuropathy Treatment market report provides useful insights for Every established and advanced players across the world. Furthermore the Ischemic Optic Neuropathy Treatment market report provides accurate analysis for the shifting competitive dynamics. This study report comprises a complete analysis of future expansion concerning the evaluation of the mentioned prediction interval. The Ischemic Optic Neuropathy Treatment market report provides a thorough study of the technological growth outlook over time to be aware of the market growth rates. The Ischemic Optic Neuropathy Treatment marketplace report also has innovative analysis of the huge number of unique factors that are boosting or functioning as well as regulating the Ischemic Optic Neuropathy Treatment marketplace growth.

A systematized methodology can be utilized to make a Report on the Global Ischemic Optic Neuropathy Treatment market. For the research of market on the terms of research Approaches, these techniques are useful. All of the Information Regarding the Products, manufacturers, vendors, clients and much more is covered in research reports. Various important factors like market trends, revenue Growth patterns market stocks and supply and demand are included in virtually all The market study report for every business. Adaptation of fresh ideas and Accepting the latest tendencies are a few the reasons for any markets growth. The Global Ischemic Optic Neuropathy Treatment market research report gives the deep understanding concerning the Regions where the market is impactful.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23077

Link:
The Surging Demand for Ischemic Optic Neuropathy Treatment in Asia-Pacific Likely to Aid the Growth of the Ischemic Optic Neuropathy Treatment Market...